Four patents currently held, every record listed here
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2037. from the record
Of the 4 now held by other companies, 3 name Universidad de la República as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2037
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2019 to 2043.
US 10,537,537
Methods of Treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic Modulators
Oct 16, 2037
US 11,400,066
Methods of Treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic Modulators
Oct 16, 2037
US 10,428,008
Nitroalkene Non Steroidal Anti-Inflammatory Drugs (NA-NSAIDS) and Methods of Treating Inflammation Related Conditions
Dec 27, 2037
US 10,906,864
Nitroalkene Non Steroidal Anti-Inflammatory Drugs (NA-NSAIDS) and Methods of Treating Inflammation Related Conditions
Dec 27, 2037
US 12,280,029
Methods Of Treatment Of Inflammation Related Conditions Using Pluripotent Anti-inflammatory And Metabolic Modulators
no later than May 30, 2038
US 12,263,143
Ionic Channel Modulation as a Method for Treating Tumors Through Inflammasome Activation
Apr 13, 2042
US 12,594,257
Means and Methods for Improving Anti-Tumoral Efficacy of Transmembrane Channel Protein Blockers
Feb 15, 2043
20242029203420392043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
10 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Dec 2037 · High confidence
Also notable
Ends Feb 2043 · High confidence
Nitroalkene Non Steroidal Anti-Inflammatory Drugs (NA-NSAIDS) and Methods of Treating Inflammation Related Conditions
US 10,428,008
Granted 2019. Computed term ends 2037.
Means and Methods for Improving Anti-Tumoral Efficacy of Transmembrane Channel Protein Blockers
US 12,594,257
Granted 2026. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Oct 2037 · High confidence
Granted 2020. Computed term ends 2037.
now held by Universidad de la República
Also notable
Ends May 2038 · High confidence
The newest of the three, granted 2022. It anchors the portfolio to 2038, later than anything else here.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 1, 2027The maintenance fee for Nitroalkene Non Steroidal Anti-Inflammatory Drugs (NA-NSAIDS) and Methods of Treating Inflammation Related Conditions (US 10,428,008) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,428,008 | Nitroalkene Non Steroidal Anti-Inflammatory Drugs (NA-NSAIDS) and Methods of Treating Inflammation Related Conditions In force · High confidence | In force | High confidence | |
| US 10,906,864 | Nitroalkene Non Steroidal Anti-Inflammatory Drugs (NA-NSAIDS) and Methods of Treating Inflammation Related Conditions In force · High confidence | In force | High confidence | |
| US 12,263,143 | Ionic Channel Modulation as a Method for Treating Tumors Through Inflammasome Activation In force · High confidence | In force | High confidence | |
| US 12,594,257 | Means and Methods for Improving Anti-Tumoral Efficacy of Transmembrane Channel Protein Blockers held by Ardan Pharma S.A.S., Universidad de la Republica Oriental Del Uruguay and Institut Pasteur de Montevideo In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 4 patents in force now held by others · 1 patent ended · 10 applications pending · 8 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed